The Indian Pharma Market (IPM) is valued at Rs 5569 crores in February 2013. It has grown at 7.4 per cent in the same month. MAT value has crossed Rs 70000 crores.
For the month of February 2013, amongst the top 10, Zydus has seen a growth at 24.3 per cent, Sun Pharma at 15 per cent, Mankind has seen a growth of 13.8 per cent and Lupin at 11.3 per cent. 21 corporates have crossed the growth of IPM for the month of February 2013.
Without bonus Sun Pharma is ranked at second for the month and MAT for February 2013 amongst corporates. Amongst the top 50 corporates, Merck has the highest growth of 43.7 per cent followed by Franco Indian at 30.5 per cent. Amongst the 11-20 ranked companies, Intas has shown high growth at 22.8 per cent followed by USV at 20.7 per cent and Ipca at 13.8 per cent.
|
With Bonus Units at Full Value
|
||||||||
|
Val in Crs
|
Rank
|
MAT Feb -13
|
Feb-13
|
|||||
|
CORPORATE
|
MAT
|
MTH
|
Val (Cr)
|
MS%
|
GR%
|
Val (Cr)
|
MS%
|
GR%
|
|
IPM
|
70287
|
100.00
|
13.0
|
5569
|
100.00
|
7.4
|
||
|
Abbott + Abbott HC + Novo
|
1
|
1
|
4736
|
6.74
|
8.6
|
376
|
6.75
|
1.6
|
|
Cipla
|
2
|
2
|
3531
|
5.02
|
8.7
|
303
|
5.43
|
6.3
|
|
Sun Pharma
|
3
|
3
|
3436
|
4.89
|
20.9
|
282
|
5.06
|
15.0
|
|
Glaxo
|
4
|
4
|
3258
|
4.64
|
14.3
|
239
|
4.30
|
0.5
|
|
Zydus + Biochem
|
5
|
5
|
3066
|
4.36
|
19.4
|
266
|
4.78
|
24.3
|
|
Ranbaxy
|
6
|
6
|
2942
|
4.19
|
9.3
|
224
|
4.02
|
6.0
|
|
Mankind
|
7
|
7
|
2549
|
3.63
|
24.9
|
201
|
3.60
|
13.8
|
|
Alkem + Cachet + Indchemie
|
8
|
8
|
2378
|
3.38
|
13.1
|
184
|
3.31
|
7.8
|
|
Pfizer + Wyeth
|
9
|
10
|
2231
|
3.17
|
14.6
|
168
|
3.02
|
1.4
|
|
Lupin
|
10
|
9
|
2137
|
3.04
|
13.9
|
175
|
3.14
|
11.3
|
|
Macleods
|
11
|
12
|
1806
|
2.57
|
23.7
|
140
|
2.52
|
11.4
|
|
Intas
|
12
|
11
|
1712
|
2.44
|
18.7
|
152
|
2.72
|
22.8
|
|
Aristo
|
13
|
15
|
1625
|
2.31
|
11.7
|
115
|
2.07
|
2.3
|
|
Emcure + Zuventus
|
14
|
13
|
1619
|
2.30
|
14.5
|
133
|
2.39
|
12.5
|
|
Sanofi-Aventis + Universal
|
15
|
14
|
1566
|
2.23
|
11.6
|
122
|
2.18
|
0.4
|
|
Glenmark
|
16
|
16
|
1383
|
1.97
|
21.4
|
113
|
2.03
|
10.3
|
|
Dr. Reddys
|
17
|
17
|
1369
|
1.95
|
8.6
|
108
|
1.94
|
1.2
|
|
Micro + Bal
|
18
|
19
|
1315
|
1.87
|
12.4
|
104
|
1.86
|
4.1
|
|
Ipca
|
19
|
22
|
1249
|
1.78
|
16.9
|
93
|
1.67
|
13.8
|
|
USV
|
20
|
18
|
1235
|
1.76
|
23.0
|
105
|
1.88
|
20.7
|
Fourrts has moved up one rank over last time to be the 49th biggest corporate in February 2013.
Amongst upcoming corporates Corona Remedies has grown at 103 per cent and have crossed Rs 150 crores, Akumentis at 37.4 per cent and Gland Pharma at 24.2 per cent.
From a therapy perspective, 11 therapies have outgrown the IPM growth. The anti-infective market has a growth of 5.1 per cent whereas respiratory market has seen a growth of seven per cent. The anti-diabetic market has grown at 9.5 per cent and cardiac at 8.2 per cent in chronic business. Amongst the top 10 therapies, the gynaecological market shows highest growth at 10.8 per cent.
|
Val in Crs
|
Val in Crs
|
Val in Crs
|
GR%
|
GR%
|
| Super Group | MAT Feb 13 |
GR%
|
Mth Feb 13 |
GR%
|
| IPM |
70287
|
13.0
|
5569
|
7.4
|
| ANTI-INFECTIVES |
12492
|
11.0
|
945
|
5.1
|
| CARDIAC |
8636
|
15.9
|
707
|
8.2
|
| GASTRO INTESTINAL |
8036
|
14.5
|
613
|
7.5
|
| VITAMINS / MINERALS / NUTRIENTS |
6203
|
14.2
|
467
|
5.3
|
| RESPIRATORY |
5344
|
9.1
|
476
|
7.0
|
| PAIN / ANALGESICS |
5217
|
10.0
|
400
|
5.9
|
| GYNAECOLOGICAL |
4608
|
10.0
|
387
|
10.8
|
| ANTI DIABETIC |
4562
|
18.1
|
372
|
9.5
|
| NEURO / CNS |
4274
|
12.6
|
351
|
8.0
|
| DERMA |
3705
|
13.8
|
289
|
5.4
|
| OPHTHAL / OTOLOGICALS |
1257
|
13.9
|
98
|
10.7
|
| HORMONES |
1205
|
18.1
|
96
|
12.9
|
| OTHERS |
3705
|
18.5
|
87
|
29.0
|
| BLOOD RELATED |
873
|
12.9
|
66
|
9.6
|
| VACCINES |
863
|
8.5
|
71
|
-4.6
|
| ANTI-NEOPLASTICS |
682
|
13.0
|
54
|
16.8
|
| ANTI MALARIALS |
648
|
17.2
|
30
|
4.1
|
| SEX STIMULANTS / REJUVENATORS |
397
|
19.1
|
34
|
11.3
|
| STOMATOLOGICALS |
314
|
13.4
|
25
|
5.0
|
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech.
AWACS in AIOCD AWACS stands for Advanced Working, Action & Correction System – reflecting the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information. Accurate and faster information flows from the market will help clients grow topline and bottom-line.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage
For more information, visit http://www.aiocd.net
